Takeda Pharmaceutical Co Stock Today
| TKPHF Stock | USD 25.26 0.29 1.14% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Takeda Pharmaceutical is trading at 25.26 as of the 24th of November 2024. This is a 1.14% down since the beginning of the trading day. The stock's lowest day price was 24.38. Takeda Pharmaceutical has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Takeda Pharmaceutical Co are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of October 2024 and ending today, the 24th of November 2024. Click here to learn more.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. The company has 1.56 B outstanding shares. More on Takeda Pharmaceutical Co
Moving against Takeda Pink Sheet
| 0.47 | WMT | Walmart Aggressive Push | PairCorr |
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Takeda Pink Sheet Highlights
| CEO | Christophe Weber |
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Takeda Pharmaceutical Co [TKPHF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Large-Cap' category with a current market capitalization of 50.37 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Takeda Pharmaceutical's market, we take the total number of its shares issued and multiply it by Takeda Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Takeda Pharmaceutical classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 1.56 B outstanding shares.
Takeda Pharmaceutical Co has accumulated about 645.99 B in cash with 1.12 T of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 417.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Takeda Pharmaceutical Probability Of Bankruptcy
Ownership AllocationTakeda Pharmaceutical shows a total of 1.56 Billion outstanding shares. 30% of Takeda Pharmaceutical outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Takeda Ownership Details
Takeda Pharmaceutical Risk Profiles
| Mean Deviation | 2.2 | |||
| Standard Deviation | 3.53 | |||
| Variance | 12.46 | |||
| Risk Adjusted Performance | 0.0041 |
Takeda Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Takeda Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
Takeda Pharmaceutical Corporate Management
| Christopher OReilly | Global Fin | Profile | |
| Andrew Plump | Chief Medical and Scientific Officer and Corporate Officer | Profile | |
| Seigo Izumo | Chair Board | Profile | |
| Gabriele Ricci | Chief Officer | Profile | |
| Salvatore Alesci | Member Policy | Profile | |
| Iwaaki Taniguchi | Sr Department | Profile |
Additional Information and Resources on Investing in Takeda Pink Sheet
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.